Effects of diet enriched with indigestible complex starch on chronic hemodialysis patients.

A clinical trial to evaluate the effects of diet enriched with indigestible/fermentable complex carbohydrates on inflammatory markers in chronic hemodialysis patients.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016062628644N1

Enrollment

Registered

2017-04-25

Start date

2016-10-25

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease, stage 5. Chronic kidney disease, stage 5

Interventions

Intervention 1: Intervention group: patients in this group will receive cakes or biscuits made with starch of high amylose, 20 gram in each day, for 2 months. Intervention 2: Control group: patients i

Prevention

Placebo

Intervention group: patients in this group will receive cakes or biscuits made with starch of high amylose, 20 gram in each day, for 2 months.

Control group: patients in this group will receive cakes or biscuits without starch of high amylose content each day, for 2 months.

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Chronic kidney disease patients who are on chronic hemodialysis for more than 6 months. Exclusion criteria: Diabetic patients; Patients who have active infection; Patients who have inflammatory diseases; Patients who are under 18 years old.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
High-density lipoprotein (HDL). Timepoint: 8 weeks following end of treatment. Method of measurement: Sampling from blood, urine and fecal of patients.;Interleukin (IL)-1b. Timepoint: 8 weeks following end of treatment. Method of measurement: Sampling from blood, urine and fecal of patients.;Interleukin (IL)-6. Timepoint: 8 weeks following end of treatment. Method of measurement: Sampling from blood, urine and fecal of patients.	—

Measure

Time frame

High-density lipoprotein (HDL). Timepoint: 8 weeks following end of treatment. Method of measurement: Sampling from blood, urine and fecal of patients.;Interleukin (IL)-1b. Timepoint: 8 weeks following end of treatment. Method of measurement: Sampling from blood, urine and fecal of patients.;Interleukin (IL)-6. Timepoint: 8 weeks following end of treatment. Method of measurement: Sampling from blood, urine and fecal of patients.

—

Secondary

Measure	Time frame
-. Timepoint: -. Method of measurement: -.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehzad Abedi

Tabriz University of Medical Sciences; Tabriz-Iran

behzad.abedi1993@gmail.com+98 41 5264 6224

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026